We recently published our article 5 Fast-Growing AI Healthcare Companies to Watch Right Now. To read the full article, head on to 10 Fast-Growing AI Healthcare Companies to Watch Right Now. In this piece, we take a closer look at Natera Inc. (NASDAQ:NTRA) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.

Artificial intelligence is no longer limited to chatbots, digital advertising and Silicon Valley experiments. It is moving into hospitals, laboratories and pharmaceutical research, where algorithms are helping scientists discover potential medicines, interpret medical images, analyze genetic information and identify treatments suited to individual patients.

Interestingly, the termx term “artificial intelligence” was introduced in 1956, but medical AI took decades to become commercially practical. Modern healthcare systems now generate enormous amounts of clinical, imaging and genomic data—the exact type of information machine-learning models are designed to analyze.

Why Medicine Could Be AI’s Next Major Market

Drug development has traditionally required years of research, costly clinical trials and thousands of unsuccessful experiments. AI drug discovery platforms cannot eliminate those risks, but they can help researchers screen molecules, predict biological interactions and prioritize the most promising candidates before expensive trials begin.

Medical imaging has also become one of the earliest real-world applications of artificial intelligence in healthcare. AI-powered diagnostics can assist doctors in detecting abnormalities, improving image quality and prioritizing urgent cases. Meanwhile, precision medicine platforms are using clinical and genomic data to help match patients with more appropriate treatments.

These developments have encouraged investors to search for the best AI healthcare stocks, AI biotech stocks and medical AI companies positioned to benefit from the industry’s long-term expansion.

A Low Share Price Does Not Always Mean Cheap

A stock trading below $10 may look affordable, but it can still be overvalued if the company generates little revenue, loses money and repeatedly issues new shares. On the other hand, a profitable healthcare technology company trading above $50 may be undervalued when its earnings, cash flow and competitive advantages support a higher valuation.

The most attractive cheap AI medicine stocks therefore combine genuine medical applications with reasonable valuations, sufficient cash reserves, improving financial performance and meaningful long-term growth opportunities.

Finding the Best AI Medicine Stocks

This ranking evaluates NYSE- and Nasdaq-listed companies based on their AI exposure, valuation, revenue growth, financial strength, clinical potential and competitive position. Higher-risk companies were penalized for heavy losses, shareholder dilution, limited cash runways and uncertain paths to profitability.

The countdown begins with the most speculative AI medicine stock at No. 10 and ends with the strongest overall risk-adjusted pick at No. 1. These companies operate across AI drug discovery, precision medicine, genomic analysis, medical imaging, digital health and clinical research—some of the most promising fields where artificial intelligence could reshape modern healthcare.

CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.

Our Methodology

For the 10 Cheap AI Medicine Stocks That Could Make You a Millionaire, we ranked each company based on its valuation, medical AI exposure, revenue growth, financial strength, clinical potential and overall investment risk.

5 Best Cheap AI Medicine Stocks to Buy Now

2. Natera Inc. (NASDAQ:NTRA)

Natera, Inc. (NASDAQ: NTRA) takes second place as the strongest combination of rapid growth, commercial scale and improving financial performance in genomic diagnostics.

The company uses genetic sequencing, proprietary algorithms and large clinical datasets across oncology, women’s health and organ health.

Its Signatera product is a personalized blood test designed to detect molecular residual disease. It looks for small amounts of tumor DNA that may remain in a patient’s bloodstream after treatment, allowing doctors to monitor whether cancer could be returning before it becomes visible through conventional imaging.

Second-quarter 2026 revenue increased approximately 38% to $752.8 million. Oncology volume reached roughly 238,000 tests as demand for Signatera continued to accelerate.

The company added around 34,000 new Signatera patients during the quarter and reported record molecular residual disease testing volume. It also benefited from growth in its women’s health and organ health businesses.

Management raised its full-year revenue forecast to between $2.85 billion and $2.91 billion. The company also expected to generate positive cash flow during 2026, an important milestone for a business that has invested aggressively in growth.

Natera, Inc. (NASDAQ: NTRA) ranks above several more obvious pure-play AI companies because its algorithms are connected to products already generating billions of dollars in annualized revenue. This is practical artificial intelligence being used within commercially validated diagnostic services.

Its growing clinical-data library may also create a reinforcing advantage. More tests can produce more data, and more data can support additional clinical studies, improved algorithms and stronger evidence for insurance reimbursement.

The risks include continued GAAP losses, premium valuation and dependence on reimbursement decisions. Genetic-testing companies must also maintain high levels of clinical accuracy because regulatory, legal or quality-control problems can quickly damage physician confidence.

Despite those concerns, Natera, Inc. (NASDAQ: NTRA) offers one of the most compelling growth profiles among Nasdaq-listed healthcare AI stocks. It narrowly misses the top position only because artificial intelligence is less visibly central to its corporate identity than it is for the No. 1 company.

YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026

Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.